Fountain Biopharma Inc.

National Taiwan University

Academia Sinica

Deutsches Krebsforschungszentrum

Tong-Young Lee

Han-Chung Wu

Chin-Tarng Lin

Kashi Javaherian

Willie Lin

Tanny Chen Tsao

Amir Abdollahi

Szu-Yao Kuo

The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Method of treating autoimmune disease by administering antibodies to interleukin-6

Uses of antibodies to interleukin-6 in cancer treatment

Antibodies to interleukin-6

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.

Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment

The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.

Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof

Growing community of inventors

Taipei, Taiwan

Tong-Young Lee